Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Dietrich Bonhoeffer We all have a longing to belong. As much as we like to be individuals, we also like people around us to identify with, connect to, share with and care for. We are not meant to ...

When a Russian and a Canadian get a standing ovation in the capital of the United States of America, you know hockey is ascended to the top of the mountain. It was a beautiful sight. The game of ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close. Contrary to what you might read on social media ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Vertex Pharmaceuticals has been the apple of investors' search engines, but its recent stock dip of 3.3% might have folks ...

As such, qCLUE marries decades of development with the quadratic speedup provided by quantum computers. We numerically test qCLUE in several scenarios, demonstrating its effectiveness and proving it ...